TY  - CONF

T1  - Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

JO  - Blood

UR  - https://doi.org/10.1182/blood-2019-122073

PY  - 2019/11/13

AU  - Uy GL

AU  - Aldoss I

AU  - Foster MC

AU  - Sallman DA

AU  - Sweet KL

AU  - Rizzieri DA

AU  - Sayre PH

AU  - Advani AS

AU  - Emadi A

AU  - Wieduwilt MJ

AU  - Vey N et al

ED  - 

DO  - DOI: 10.1182/blood-2019-122073

PB  - American Society of Hematology

VL  - 134

IS  - Supplement_1

SP  - 733

EP  - 733

Y2  - 2026/02/25

ER  -